129 related articles for article (PubMed ID: 34993673)
1. Maximum standardized uptake value change rate before and after neoadjuvant chemotherapy can predict early recurrence in patients with locally advanced esophageal cancer: a multi-institutional cohort study of 220 patients in Japan.
Murakami K; Yoshida N; Taniyama Y; Takahashi K; Toyozumi T; Uno T; Kamei T; Baba H; Matsubara H
Esophagus; 2022 Apr; 19(2):205-213. PubMed ID: 34993673
[TBL] [Abstract][Full Text] [Related]
2. Correlation Between Tumor Uptake on FDG-PET and Malignant Features in Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery.
Hamai Y; Emi M; Ibuki Y; Kurokawa T; Yoshikawa T; Ohsawa M; Hirohata R; Kitasaki N; Okada M
Anticancer Res; 2022 Dec; 42(12):6037-6045. PubMed ID: 36456150
[TBL] [Abstract][Full Text] [Related]
3. Ability of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography to Predict Outcomes of Neoadjuvant Chemoradiotherapy Followed by Surgical Treatment for Esophageal Squamous Cell Carcinoma.
Hamai Y; Hihara J; Emi M; Furukawa T; Yamakita I; Kurokawa T; Okada M
Ann Thorac Surg; 2016 Oct; 102(4):1132-9. PubMed ID: 27319990
[TBL] [Abstract][Full Text] [Related]
4. Total Lesion Glycolysis Ratio in Positron Emission Tomography/Computed Tomography Images During Neoadjuvant Chemotherapy Can Predict Pathological Tumor Regression Grade and Prognosis in Patients with Locally Advanced Squamous Cell Carcinoma of the Esophagus.
Sonoda A; Yoshida N; Shiraishi S; Horinouchi T; Tokunaga R; Harada K; Iwatsuki M; Nagai Y; Baba Y; Iwagami S; Miyamoto Y; Baba H
Ann Surg Oncol; 2021 Jan; 28(1):167-174. PubMed ID: 32588261
[TBL] [Abstract][Full Text] [Related]
5. Predictive Ability of
Kiyoto S; Sugawara Y; Hosokawa K; Nishimura R; Yamashita N; Ohsumi S; Mochizuki T
Asia Ocean J Nucl Med Biol; 2016; 4(1):3-11. PubMed ID: 27904868
[TBL] [Abstract][Full Text] [Related]
6. Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.
Higuchi I; Yasuda T; Yano M; Doki Y; Miyata H; Tatsumi M; Fukunaga H; Takiguchi S; Fujiwara Y; Hatazawa J; Monden M
J Thorac Cardiovasc Surg; 2008 Jul; 136(1):205-12, 212.e1-3. PubMed ID: 18603077
[TBL] [Abstract][Full Text] [Related]
7. Predictions of Pathological Features and Recurrence Based on FDG-PET Findings of Esophageal Squamous Cell Carcinoma after Trimodal Therapy.
Hamai Y; Emi M; Ibuki Y; Murakami Y; Nishibuchi I; Nagata Y; Furukawa T; Kurokawa T; Ohsawa M; Yoshikawa T; Okada M
Ann Surg Oncol; 2020 Oct; 27(11):4422-4430. PubMed ID: 32405978
[TBL] [Abstract][Full Text] [Related]
8. Metabolic Tumor Volume Change Predicts Long-term Survival and Histological Response to Preoperative Chemotherapy in Locally Advanced Esophageal Cancer.
Makino T; Yamasaki M; Tanaka K; Masuike Y; Tatsumi M; Motoori M; Kimura Y; Hatazawa J; Mori M; Doki Y
Ann Surg; 2019 Dec; 270(6):1090-1095. PubMed ID: 29727327
[TBL] [Abstract][Full Text] [Related]
9. Prognostic relevance of ¹⁸F-FDG PET uptake in patients with locally advanced, extremity soft tissue sarcomas undergoing neoadjuvant isolated limb perfusion with TNF-α and melphalan.
Andreou D; Boldt H; Pink D; Jobke B; Werner M; Schuler M; Reichardt P; Tunn PU
Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1076-83. PubMed ID: 24519553
[TBL] [Abstract][Full Text] [Related]
10.
Mi L; Zhao Y; Zhao X; Yin F; Yin X; Li N; Shi J; Han X; Duan X; Zhao M; Han G; Wang J
Cancer Biother Radiopharm; 2021 Oct; 36(8):662-671. PubMed ID: 32783634
[No Abstract] [Full Text] [Related]
11. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer.
Vallböhmer D; Hölscher AH; Dietlein M; Bollschweiler E; Baldus SE; Mönig SP; Metzger R; Schicha H; Schmidt M
Ann Surg; 2009 Dec; 250(6):888-94. PubMed ID: 19953708
[TBL] [Abstract][Full Text] [Related]
12. The Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer.
Lee HW; Lee HM; Choi SE; Yoo H; Ahn SG; Lee MK; Jeong J; Jung WH
J Nucl Med; 2016 Aug; 57(8):1183-8. PubMed ID: 27033896
[TBL] [Abstract][Full Text] [Related]
13. [Utility and drawbacks of fludeoxyglucose-positron emission tomography in locally advanced esophageal cancer treated by neoadjuvant chemotherapy followed by esophagectomy].
Takemura M; Yamashita H; Kaibe N; Takii M; Niwa H; Oshima T; Kikuchi S; Sasako M
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2143-5. PubMed ID: 24394040
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Significance of (18)F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET)-Positive Lymph Nodes Following Neoadjuvant Chemotherapy and Surgery for Resectable Thoracic Esophageal Squamous Cell Carcinoma.
Yasuda T; Yano M; Miyata H; Yamasaki M; Takiguchi S; Fujiwara Y; Doki Y
Ann Surg Oncol; 2015 Aug; 22(8):2599-607. PubMed ID: 25524011
[TBL] [Abstract][Full Text] [Related]
15. Temporal validation of metabolic nodal response of esophageal cancer to neoadjuvant chemotherapy as an independent predictor of unresectable disease, survival, and recurrence.
Findlay JM; Dickson E; Fiorani C; Bradley KM; Mukherjee S; Gillies RS; Maynard ND; Middleton MR
Eur Radiol; 2019 Dec; 29(12):6717-6727. PubMed ID: 31278574
[TBL] [Abstract][Full Text] [Related]
16. Utility of positron emission-computed tomography for predicting pathological response in resectable oesophageal squamous cell carcinoma after neoadjuvant chemoradiation.
Lee J; Choi JY; Lim SW; Ahn MJ; Park K; Zo JI; Shim YM; Oh D; Sun JM
Eur J Cardiothorac Surg; 2020 Nov; 58(5):1019-1026. PubMed ID: 32920638
[TBL] [Abstract][Full Text] [Related]
17. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
[TBL] [Abstract][Full Text] [Related]
18. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
[TBL] [Abstract][Full Text] [Related]
19. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
[TBL] [Abstract][Full Text] [Related]
20. Systemic control and evaluation of the response to neoadjuvant chemotherapy in resectable thoracic esophageal squamous cell carcinoma with ¹⁸F-fluorodeoxyglucose positron emission tomography-positive lymph nodes.
Yasuda T; Yano M; Miyata H; Yamasaki M; Higuchi I; Takiguchi S; Fujiwara Y; Doki Y
Surg Today; 2015 Mar; 45(3):335-45. PubMed ID: 24969049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
